Topotecan Hydrochloride Chemical Structure (Topotecan Image1)
Topotecan Hydrochloride Injection, Powder, Lyophilized, For Solution
Product Images NDC 16729-151
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topotecan Hydrochloride (NDC 16729-151). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Accord Healthcare, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1. Kaplan-meier Curves For Overall Survival In Cervical Cancer In Study Gog 0179 (Topotecan Image2)
This is a graph showing the effectiveness of topotecan hydrochloride for injection in combination with cisplatin compared to cisplatin monotherapy over a period of 35 months. The y-axis represents the number of participants in the study who were at risk, while the x-axis represents the number of months on the study. The graph shows that the combination of topotecan hydrochloride and cisplatin resulted in a higher number of participants remaining at risk for a longer period of time compared to cisplatin alone.*
Topotecan Injection Label (Topotecan Image3)
This text appears to be a mixture of medical and product information related to a drug called "Topotecan Hydrochloride". The text mentions dosage instructions, precautions, and side effects of the drug. It also talks about how to handle and store the drug, including its sensitivity to light. The text advises to wash injection contacts thoroughly and flush mucous membranes with water. It also warns that the drug is cytotoxic and has batch coding.*
Topotecan Injection Label (Topotecan Image4)
This is a description of Topotecan Hydrochloride for Injection, a medication for intravenous use. The drug is contained in a single dose vial and must be diluted. The medication is manufactured by Accord Healthcare in Durham, NC and by Intas Pharmaceuticals Limited in Anmedabag-382 210, India. The vial contains topotecan hydrochloride equivalent to 4mg of topotecan rebase, 48mg mannitol, and other substances. The medication should be stored at 20 to 25°C and protected from light. The safe handling of the medication is important and certain precautions should be taken. The recommended dosage for the medication should be followed as indicated in the prescribing information.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
